Xanthus Receives Orphan Drug Designation for Oral Fludarabine
Posted on: Friday, 4 January 2008, 09:00 CST
The FDA has granted orphan drug designation to Xanthus Pharmaceuticals's fludarabine phosphate oral tablets for the treatment of B-cell chronic lymphocytic leukemia.
The FDA grants orphan designation to products that are intended to address diseases affecting fewer than 200,000 persons in the US. If oral fludarabine receives FDA approval, this designation will entitle Xanthus to exclusive marketing rights for oral fludarabine for the treatment of chronic lymphocytic leukemia (CLL) for seven years following the NDA approval, except in limited circumstances.
Richard Dean, CEO of Xanthus, said: "We are pleased to receive orphan drug designation for oral fludarabine. With the convenience of oral dosing and a strong body of clinical efficacy and tolerability data already behind it, we believe oral fludarabine represents an exciting opportunity for Xanthus."
Source: Datamonitor
Related Articles
- FDA to Review Xanthus's Oral Fludarabine NDA
- Xanthus Announces Oral Fludarabine NDA Accepted for Review By U.S. FDA
- Xanthus Receives Orphan Drug Designation for Oral Fludarabine for the Treatment of CLL
- Aastrom Receives Orphan Drug Designation From FDA for Dilated Cardiomyopathy
- Gentium Receives Orphan Drug Designation From FDA for Defibrotide to Prevent Hepatic Veno-Occlusive Disease
- Provectus Receives Orphan Drug Designation From FDA for Anti-Cancer Agent PV-10 for the Treatment Of Metastatic Melanoma
- Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
- Xanthus Pharmaceuticals Expands Oncology Pipeline With Late-Stage Oral Fludarabine From Schering AG
- TolerRx Receives Orphan Drug Designation From FDA for TRX4 for the Treatment of New-Onset Type 1 Diabetes
 |
 |
User Comments (0)
RSS Feeds